https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

V116 Well-Tolerated With Broad Immune Responses in Pneumococcal Vaccine-Naïve Older Adults

V116 Well-Tolerated With Broad Immune Responses in Pneumococcal Vaccine-Naïve Older Adults

In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination.

administrator

Related Articles